摘要: Papers p 465 In spite of a worldwide intensification the battle against tobacco consumption, incidence lung cancer continues to rise in parallel with increased consumption tobacco. This is especially so women Western countries and men developing countries. Major strides have been made our knowledge biology cancer. But we still await impact this information on prevention, early diagnosis, cure rate, which has essentially unchanged during past couple decades, five year survival rate for non-small cell 8-14%. The figures vary somewhat from country country, almost half patients dying within first diagnosis best clinical treatments.1 Non-small includes squamous carcinoma, adenocarcinoma, large carcinoma. It accounts 75-80% all new patients; remaining are small carcinomas. Of …
highwire.org参考文章(10)
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
Robert S. Pritchard, Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer Annals of Internal Medicine. ,vol. 125, pp. 723- 729 ,(1996) , 10.7326/0003-4819-125-9-199611010-00003
Pietro Marino, Armando Preatoni, Alessandra Cantoni, Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta‐analysis Cancer. ,vol. 76, pp. 593- 601 ,(1996) , 10.1002/1097-0142(19950815)76:4<593::AID-CNCR2820760409>3.0.CO;2-N
Desmond N. Carney, Heine H. Hansen, Non-small-cell lung cancer--stalemate or progress? The New England Journal of Medicine. ,vol. 343, pp. 1261- 1262 ,(2000) , 10.1056/NEJM200010263431710
D. P Carbone, J. D Minna, Chemotherapy for non-small cell lung cancer BMJ. ,vol. 311, pp. 889- 890 ,(1995) , 10.1136/BMJ.311.7010.889
Stephen J Falk, David J Girling, Roger J White, Penelope Hopwood, Angela Harvey, Wendi Qian, Richard J Stephens, Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial BMJ. ,vol. 325, pp. 465- 465 ,(2002) , 10.1136/BMJ.325.7362.465
F Macbeth, E Toy, B Coles, A Melville, A Eastwood, Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database of Systematic Reviews. ,(2001) , 10.1002/14651858.CD002143
J.P. Bernard, P.J. Souquet, J.P. Boissel, F. Chauvin, R. Cellerino, D. Tumarello, Y. Cormier, P.A. Ganz, S. Kaasa, J.L. Pater, E. Quoix, E. Rapp, J. Williams, B.L. Woods, Polychemotherapy in advanced non-small cell lung cancer : a meta-analysis The Lancet. ,vol. 342, pp. 19- 21 ,(1993) , 10.1016/0140-6736(93)91882-M
Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, Karin Mattson, Richard Gralla, Mark O’Rourke, Nathan Levitan, Laurent Gressot, Mark Vincent, Ronald Burkes, Susan Coughlin, Yong Kim, Jocelyne Berille, Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Journal of Clinical Oncology. ,vol. 18, pp. 2095- 2103 ,(2000) , 10.1200/JCO.2000.18.10.2095
R. Rosell, Managing poor performance non-small-cell lung cancer patients. Annals of Oncology. ,vol. 12, pp. 1659- 1661 ,(2001) , 10.1023/A:1013576914283